Travere Therapeutics (TVTX) soared to a new high on Friday, fueled by strong earnings and a positive outlook. The stock hit $35.34 before closing at $35.16, up 18.58%. Revenues surged 162% to $164.8 million, with Filspari contributing $90.9 million in US sales. CEO Eric Dube praised the commercial success and future prospects.

Read more at Yahoo Finance: Travere Therapeutics (TVTX) Hits Fresh High on Impressive Earnings, Bullish Outlook